Canaccord Genuity analyst Edward Nash has maintained their bullish stance on VTYX stock, giving a Buy rating on November 8. Edward ...

Oppenheimer analyst Jeff Jones maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target of ...

Ventyx Biosciences (NASDAQ:VTYX) files prospectus the offer and resale from time to time of up to 7,060,100 shares of common stock. SEC Filing More on Ventyx Biosciences Ventyx Biosciences: R ...

Revenue in Q3 2024 decreased by $3.8 million to $61.6 million as compared to $65.4 million in Q3 2023. The year-over-year decrease in revenue can primarily be attributed to a decrease in retail ...

Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson’s disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors ...

Ventyx stock shows all the characteristics of a highly underappreciated issue with surprisingly valuable assets that can be ...

China Universal Asset Management Co. Ltd. lifted its stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report) by 64.1% ...

Wells Fargo has recently raised Ventyx Biosciences Inc (VTYX) stock to Overweight rating, as announced on March 12, 2024, according to Finviz. Earlier, on March 12, 2024, Oppenheimer had raised the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ventyx Biosciences stock opened at $2.57 on Tuesday. The stock has a market cap of $181.62 million, a P/E ratio of -0.92 and a beta of 0.36. The company has a 50-day moving average price of $2.17 ...

Ventyx Biosciences Inc (NASDAQ:VTYX) retained its Neutral rating and a price target of $6.00, as confirmed by H.C. Wainwright. The decision follows the presentation of long-term efficacy (LTE) data ...